Outcomes researcher moves south to national nonprofit

Share this article:
Dave Davis, MD, the University of Toronto academic widely respected for his research on outcomes-oriented education, will join the Washington, DC-based Association of American Medical Colleges.

Davis will assume a new position for this nonprofit association—VP, continuing health
education and physician performance improvement in the division of med ed. AAMC oversees several initiatives aimed at improving med ed.

Davis, who currently leads the University of Toronto CME program, said he will work to up awareness of CME, its effectiveness and linkages to the health system. “To have an opportunity at the end of my career to spend time with colleagues who I value in CME across the nation is just a wonderful opportunity,” Davis told MM&M.

The announcement follows part of a sabbatical year Davis spent at AAMC.

ACCME’s updated compliance criteria also prompted the move. “It made me think some of these goals might be attained,” Davis said.

Davis’ current duties have included overseeing a knowledge translation program endowed by Li Ka Shing at Toronto’s St. Michael’s Hospital. He earlier created a CE division at Canada’s McMaster University. Davis said that, in some medical schools, QI in patient care and CME are not meshed well. “Clearly we need to bring those two dimensions together.”

He will begin his new post in late summer or fall as soon as he winds down his medical practice.
Davis will report to Carol Aschenbrener, MD, AAMC EVP.

Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.